U.S. FDA Approves Sanofi's Bleeding Disorder Therapy
The US FDA has approved Sanofi's therapy, Altuviiio, for hemophilia A, a type of inherited bleeding disorder. Altuviiio is expected to be launched in the US in April and is likely to be one of the best in its class, according to an analyst. The average annual cost of existing clotting factor therapies is approximately $300,000, and Sanofi will price Altuviiio at parity with the annual cost of treating a prophylaxis patient on Eloctate. Altuviiio is expected to compete with other factor replacement therapies, including those from Takeda Pharmaceutical, Bayer, and Novo Nordisk.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
